Executive summary The 2024 update of the Lancet Commission on dementia provides new
hopeful evidence about dementia prevention, intervention, and care. As people live longer …

Parkinson's disease and dementia with Lewy bodies are currently defined by their clinical
features, with α-synuclein pathology as the gold standard to establish the definitive …

Extracellular vesicles (EVs), through their complex cargo, can reflect the state of their cell of
origin and change the functions and phenotypes of other cells. These features indicate …

This study aimed to evaluate the impact of APOE4 homozygosity on Alzheimer's disease
(AD) by examining its clinical, pathological and biomarker changes to see whether APOE4 …

Background Trials of monoclonal antibodies that target various forms of amyloid at different
stages of Alzheimer's disease have had mixed results. Methods We tested solanezumab …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Increasing evidence points to a pivotal role of immune processes in the pathogenesis of
Alzheimer disease, which is the most prevalent neurodegenerative and dementia-causing …

Importance There are limited efficacious treatments for Alzheimer disease. Objective To
assess efficacy and adverse events of donanemab, an antibody designed to clear brain …

Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

An unresolved question for the understanding of Alzheimer's disease (AD) pathophysiology
is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) …